Cargando…

A French National Survey on Clotting Disorders in Mastocytosis

Mastocytosis is characterized by a clonal mast cell proliferation with organ infiltration and uncontrolled degranulation. Although not characteristic and poorly explained, some patients develop clotting abnormalities. We retrospectively identified patients with established diagnosis of mastocytosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalhosa, Ana B., Aouba, Achille, Damaj, Gandhi, Canioni, Danielle, Brouzes, Chantal, Gyan, Emmanuel, Durupt, Stéphane, Durieu, Isabelle, Cathebras, Pascal, Costédoat-Chalumeau, Nathalie, Launay, David, Pilmis, Benoit, Barete, Stephane, Frenzel, Laurent, Lortholary, Olivier, Hermine, Olivier, Hermans, Cedric, Chandesris, Marie-Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616764/
https://www.ncbi.nlm.nih.gov/pubmed/26447996
http://dx.doi.org/10.1097/MD.0000000000001414
_version_ 1782396707448815616
author Carvalhosa, Ana B.
Aouba, Achille
Damaj, Gandhi
Canioni, Danielle
Brouzes, Chantal
Gyan, Emmanuel
Durupt, Stéphane
Durieu, Isabelle
Cathebras, Pascal
Costédoat-Chalumeau, Nathalie
Launay, David
Pilmis, Benoit
Barete, Stephane
Frenzel, Laurent
Lortholary, Olivier
Hermine, Olivier
Hermans, Cedric
Chandesris, Marie-Olivia
author_facet Carvalhosa, Ana B.
Aouba, Achille
Damaj, Gandhi
Canioni, Danielle
Brouzes, Chantal
Gyan, Emmanuel
Durupt, Stéphane
Durieu, Isabelle
Cathebras, Pascal
Costédoat-Chalumeau, Nathalie
Launay, David
Pilmis, Benoit
Barete, Stephane
Frenzel, Laurent
Lortholary, Olivier
Hermine, Olivier
Hermans, Cedric
Chandesris, Marie-Olivia
author_sort Carvalhosa, Ana B.
collection PubMed
description Mastocytosis is characterized by a clonal mast cell proliferation with organ infiltration and uncontrolled degranulation. Although not characteristic and poorly explained, some patients develop clotting abnormalities. We retrospectively identified patients with established diagnosis of mastocytosis and related clotting abnormalities (clinical and/or biological) using the national French Reference Centre for Mastocytosis database. From our cohort of 14 adult patients with clotting abnormalities (median age 46 years [range 26–75]), 4 had a presentation suggestive of a primary hemostasis disorder alone (by their symptoms and/or abnormal clotting tests [PFA, von Willebrand's disease [vWD] screening]) and 10 had a laboratory impairment of secondary hemostasis. Among these, 7 had bleeds characteristic of a coagulation cascade disorder (severe/life-threatening in 5 and mild in 2 patients). Clotting abnormalities were of variable severity, typically related to intense crisis of degranulation, such as anaphylactic reactions, and/or to severe organ infiltration by mast cells. Importantly, classical hemostatic management with platelet transfusion, fresh frozen plasma, or vitamin K infusions was unsuccessful, as opposed to the use of agents inhibiting mast cell activity, particularly steroids. This illustrates the crucial role of mast cell mediators such as tryptase and heparin, which interfere both with primary (mainly via inhibition of von Willebrand factor) and secondary hemostasis. There was interestingly an unusually high number of aggressive mastocytosis (particularly mast cell leukemia) and increased mortality in the group with secondary hemostasis disorders (n = 5, 36% of the whole cohort). Mast cell degranulation and/or high tumoral burden induce both specific biologic antiaggregant and anticoagulant states with a wide clinical spectrum ranging from asymptomatic to life-threatening bleeds. Hemostatic control is achieved by mast cell inhibitors such as steroids.
format Online
Article
Text
id pubmed-4616764
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46167642015-10-27 A French National Survey on Clotting Disorders in Mastocytosis Carvalhosa, Ana B. Aouba, Achille Damaj, Gandhi Canioni, Danielle Brouzes, Chantal Gyan, Emmanuel Durupt, Stéphane Durieu, Isabelle Cathebras, Pascal Costédoat-Chalumeau, Nathalie Launay, David Pilmis, Benoit Barete, Stephane Frenzel, Laurent Lortholary, Olivier Hermine, Olivier Hermans, Cedric Chandesris, Marie-Olivia Medicine (Baltimore) 4800 Mastocytosis is characterized by a clonal mast cell proliferation with organ infiltration and uncontrolled degranulation. Although not characteristic and poorly explained, some patients develop clotting abnormalities. We retrospectively identified patients with established diagnosis of mastocytosis and related clotting abnormalities (clinical and/or biological) using the national French Reference Centre for Mastocytosis database. From our cohort of 14 adult patients with clotting abnormalities (median age 46 years [range 26–75]), 4 had a presentation suggestive of a primary hemostasis disorder alone (by their symptoms and/or abnormal clotting tests [PFA, von Willebrand's disease [vWD] screening]) and 10 had a laboratory impairment of secondary hemostasis. Among these, 7 had bleeds characteristic of a coagulation cascade disorder (severe/life-threatening in 5 and mild in 2 patients). Clotting abnormalities were of variable severity, typically related to intense crisis of degranulation, such as anaphylactic reactions, and/or to severe organ infiltration by mast cells. Importantly, classical hemostatic management with platelet transfusion, fresh frozen plasma, or vitamin K infusions was unsuccessful, as opposed to the use of agents inhibiting mast cell activity, particularly steroids. This illustrates the crucial role of mast cell mediators such as tryptase and heparin, which interfere both with primary (mainly via inhibition of von Willebrand factor) and secondary hemostasis. There was interestingly an unusually high number of aggressive mastocytosis (particularly mast cell leukemia) and increased mortality in the group with secondary hemostasis disorders (n = 5, 36% of the whole cohort). Mast cell degranulation and/or high tumoral burden induce both specific biologic antiaggregant and anticoagulant states with a wide clinical spectrum ranging from asymptomatic to life-threatening bleeds. Hemostatic control is achieved by mast cell inhibitors such as steroids. Wolters Kluwer Health 2015-10-09 /pmc/articles/PMC4616764/ /pubmed/26447996 http://dx.doi.org/10.1097/MD.0000000000001414 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4800
Carvalhosa, Ana B.
Aouba, Achille
Damaj, Gandhi
Canioni, Danielle
Brouzes, Chantal
Gyan, Emmanuel
Durupt, Stéphane
Durieu, Isabelle
Cathebras, Pascal
Costédoat-Chalumeau, Nathalie
Launay, David
Pilmis, Benoit
Barete, Stephane
Frenzel, Laurent
Lortholary, Olivier
Hermine, Olivier
Hermans, Cedric
Chandesris, Marie-Olivia
A French National Survey on Clotting Disorders in Mastocytosis
title A French National Survey on Clotting Disorders in Mastocytosis
title_full A French National Survey on Clotting Disorders in Mastocytosis
title_fullStr A French National Survey on Clotting Disorders in Mastocytosis
title_full_unstemmed A French National Survey on Clotting Disorders in Mastocytosis
title_short A French National Survey on Clotting Disorders in Mastocytosis
title_sort french national survey on clotting disorders in mastocytosis
topic 4800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616764/
https://www.ncbi.nlm.nih.gov/pubmed/26447996
http://dx.doi.org/10.1097/MD.0000000000001414
work_keys_str_mv AT carvalhosaanab afrenchnationalsurveyonclottingdisordersinmastocytosis
AT aoubaachille afrenchnationalsurveyonclottingdisordersinmastocytosis
AT damajgandhi afrenchnationalsurveyonclottingdisordersinmastocytosis
AT canionidanielle afrenchnationalsurveyonclottingdisordersinmastocytosis
AT brouzeschantal afrenchnationalsurveyonclottingdisordersinmastocytosis
AT gyanemmanuel afrenchnationalsurveyonclottingdisordersinmastocytosis
AT duruptstephane afrenchnationalsurveyonclottingdisordersinmastocytosis
AT durieuisabelle afrenchnationalsurveyonclottingdisordersinmastocytosis
AT cathebraspascal afrenchnationalsurveyonclottingdisordersinmastocytosis
AT costedoatchalumeaunathalie afrenchnationalsurveyonclottingdisordersinmastocytosis
AT launaydavid afrenchnationalsurveyonclottingdisordersinmastocytosis
AT pilmisbenoit afrenchnationalsurveyonclottingdisordersinmastocytosis
AT baretestephane afrenchnationalsurveyonclottingdisordersinmastocytosis
AT frenzellaurent afrenchnationalsurveyonclottingdisordersinmastocytosis
AT lortholaryolivier afrenchnationalsurveyonclottingdisordersinmastocytosis
AT hermineolivier afrenchnationalsurveyonclottingdisordersinmastocytosis
AT hermanscedric afrenchnationalsurveyonclottingdisordersinmastocytosis
AT chandesrismarieolivia afrenchnationalsurveyonclottingdisordersinmastocytosis
AT carvalhosaanab frenchnationalsurveyonclottingdisordersinmastocytosis
AT aoubaachille frenchnationalsurveyonclottingdisordersinmastocytosis
AT damajgandhi frenchnationalsurveyonclottingdisordersinmastocytosis
AT canionidanielle frenchnationalsurveyonclottingdisordersinmastocytosis
AT brouzeschantal frenchnationalsurveyonclottingdisordersinmastocytosis
AT gyanemmanuel frenchnationalsurveyonclottingdisordersinmastocytosis
AT duruptstephane frenchnationalsurveyonclottingdisordersinmastocytosis
AT durieuisabelle frenchnationalsurveyonclottingdisordersinmastocytosis
AT cathebraspascal frenchnationalsurveyonclottingdisordersinmastocytosis
AT costedoatchalumeaunathalie frenchnationalsurveyonclottingdisordersinmastocytosis
AT launaydavid frenchnationalsurveyonclottingdisordersinmastocytosis
AT pilmisbenoit frenchnationalsurveyonclottingdisordersinmastocytosis
AT baretestephane frenchnationalsurveyonclottingdisordersinmastocytosis
AT frenzellaurent frenchnationalsurveyonclottingdisordersinmastocytosis
AT lortholaryolivier frenchnationalsurveyonclottingdisordersinmastocytosis
AT hermineolivier frenchnationalsurveyonclottingdisordersinmastocytosis
AT hermanscedric frenchnationalsurveyonclottingdisordersinmastocytosis
AT chandesrismarieolivia frenchnationalsurveyonclottingdisordersinmastocytosis